Cardiff Oncology (NASDAQ:CRDF) Issues Earnings Results

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05, Zacks reports. Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. The firm had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.09 million.

Cardiff Oncology Stock Down 9.9 %

Shares of CRDF traded down $0.42 during trading hours on Monday, hitting $3.82. The company had a trading volume of 1,273,632 shares, compared to its average volume of 1,177,694. Cardiff Oncology has a 52-week low of $2.01 and a 52-week high of $6.42. The stock's 50 day moving average price is $4.06 and its 200 day moving average price is $3.24. The firm has a market cap of $195.33 million, a P/E ratio of -4.06 and a beta of 1.77.

Insider Activity

In other Cardiff Oncology news, Director Gary W. Pace bought 350,115 shares of the business's stock in a transaction that occurred on Wednesday, December 11th. The shares were bought at an average cost of $2.60 per share, with a total value of $910,299.00. Following the completion of the purchase, the director now directly owns 1,047,876 shares of the company's stock, valued at $2,724,477.60. This trade represents a 50.18 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 7.80% of the company's stock.

Analyst Upgrades and Downgrades

CRDF has been the topic of several research analyst reports. HC Wainwright upped their price target on shares of Cardiff Oncology from $13.00 to $17.00 and gave the stock a "buy" rating in a report on Friday. Piper Sandler lifted their price target on Cardiff Oncology from $7.00 to $10.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.